25 results about "HBeAg" patented technology

The invention discloses a medicine for removing SHBs / HBsAg protein and a preparation method thereof, and relates to the technical field of biology, the medicine comprises a recombinant plasmid of a TRIM21 gene and / or OTUD4 small interfering RNA; the preparation method comprises the following steps: synthesizing a TRIM21 gene and cloning the TRIM21 gene to an expression vector to obtain a recombinant plasmid; synthesizing a small interfering RNA (Ribonucleic Acid) of the OTUD4 gene; and transfecting the constructed recombinant plasmid or the synthesized small interfering RNA into liver cancer cells for expressing SHBs protein or HBV (Hepatitis B Virus). According to the present invention, the construction of the recombinant vector pcDNATM3.1 / myc-His (-) A-TRIM21-myc and the construction of the OTUD4 siRNA are constructed; overexpression of TRIM21 or knockout of OTUD4 can significantly inhibit expression of SHBs / HBsAg protein in liver cancer cells, expression of HBsAg and HBeAg protein secreted out of the cells and the HBV DNA level.

The present disclosure relates to siRNA for inhibiting hepatitis B virus and uses thereof. In particular to an oligonucleotide for inhibiting HBV or a pharmaceutically acceptable salt thereof, the oligonucleotide comprises an antisense strand, the antisense strand comprises at least one modified nucleotide, and the nucleotide sequence of the antisense strand comprises a sequence or fragment as shown in any one of SEQ ID NO: 3-35. According to the present invention, the siRNA provides significant inhibition effects for HBsAg, HBV DNA and HBeAg generated by cccDNA and host genome integrated HBV DNA in vivo and in vitro, the drug effect is lasting, and compared with the original sequence, the optimized sequence improves the inhibition effect and the drug effect period, and reduces the off-target toxicity;

The invention relates to the technical field of chemistry and medicine, in particular to application of two phenylethanoid glycoside compounds in Pensamie in anti-hepatitis B virus and liver protection, including application of forsythiaside F and forsythiaside B in preparation of anti-hepatitis B virus drugs and / or application of forsythiaside F and forsythiaside B in preparation of liver protection drugs. According to the invention, two compounds of forsythiaside F and forsythiaside B are obtained from 75% ethanol extract of separated and purified Tibesimie, the properties of the two compounds are researched, and the two compounds are found to be capable of reducing HBsAg and HBeAg and have a certain liver protection effect, so that data are provided for development and utilization of Tibesimie and research and development of anti-hepatitis B virus drugs, and the research and development of the Tibesimie and the research and development of the anti-hepatitis B virus drugs are facilitated. And a new way is provided for HBV prevention and treatment.

The invention discloses an application of TFPI2 in preparation of an anti-hepatitis B virus drug. Through in-depth study, it is found for the first time that overexpressed TFPI2 can significantly inhibit the replication ability of HBV on the cellular level and the animal level, and the expression level of HBV DNA and HBV RNA and the secretion level of HBsAg and HBeAg are reduced. Besides, mechanism analysis finds that overexpression TFPI2 promotes degradation of hepatitis B virus X protein (HBx), the half-life period of the HBx protein is remarkably shortened, and finally the HBV replication ability is damaged. Based on the research results, the application of the TFPI2 in chronic viral hepatitis B is provided for the first time, and candidate treatment targets and backup protein drugs are provided for clinical treatment of chronic hepatitis B patients.

The invention discloses a mini-chromosome state characterization cell model for drug screening. The mini-chromosome state characterization cell model is a transfected cell obtained by co-transfecting a hepatocyte line with prcccDNA-HiBiT-HBx and a plasmid Cre; the invention also discloses an application of the compound C20H14F3N3S or the pharmaceutically acceptable salt thereof in preparation of an HBV (hepatitis B virus) inhibitor or a medicine for treating hepatitis B virus infectious diseases or symptoms. According to the invention, a novel anti-hepatitis B virus small molecule compound is screened by utilizing a constructed cell model, and experiments prove that the novel anti-hepatitis B virus small molecule compound can obviously reduce the expression levels of HBV total RNAs, HBeAg, HBV pgRNA and HBV nucleoprotein.

The invention discloses an application of a small molecule compound in inhibiting HBV (Hepatitis B Virus) replication and treating hepatitis B. According to the application of the small molecule compound C18H12F3N3OS in resisting hepatitis B virus (HBV) provided by the invention, systematic in-vitro and in-vivo experiments prove that the compound can effectively inhibit the replication and expression of the HBV through a multi-target action mechanism. Experimental data show that the compound can significantly reduce the total virus RNAs level in HBV infected cells and the expression level of HBVpgRNA and HBc proteins under the micromolar concentration, and can reduce the expression of HBeAg in a dose-dependent manner. The small molecule compound has the advantages of good chemical structure solubility and low toxicity (CC50gt; and the compound is expected to be applied to clinical transformation of anti-HBV drugs.

The present invention relates to the use of ciprofibrate in the preparation of a drug for anti-hepatitis B virus, belonging to the field of biomedical technology. The present invention provides the use of ciprofibrate in the preparation of a drug for anti-hepatitis B virus. Ciprofibrate reduces the expression levels of hepatitis B surface antigen HBsAg, hepatitis B e antigen HBeAg, and hepatitis B core antigen HBcAg in human primary cells infected with hepatitis B virus, inhibits hepatitis B virus from infecting cells, inhibits the proliferation and replication of hepatitis B virus, can protect neonatal hepatocytes from being reinfected, has an anti-hepatitis B virus effect, and thus prevents and treats diseases caused by hepatitis B virus. Ciprofibrate, as a lipid-regulating drug, has minor side effects, does not require subcutaneous injection, and has high patient compliance.

The invention relates to application of an extracellular matrix protein 1 in preparation of a medicine for treating HBV infection, and belongs to the technical field of biological medicine. The invention provides application of an extracellular matrix protein 1 and / or an extracellular matrix protein 1 accelerant in preparation of drugs for preventing and / or treating HBV infection and related diseases caused by HBV infection. Experiments show that the intrahepatic overexpression extracellular matrix protein 1 can significantly reduce the level of HBsAg and HBeAg in an HBV mouse body and promote the generation of HBsAb in the HBV mouse body; meanwhile, the levels of HBsAg and HBeAg in the HBV mouse can also be remarkably reduced by utilizing the expression of the extracellular matrix protein 1 in the hepatic stellate cells of the HBV mouse and the exogenous supplement of the extracellular matrix protein 1 to the HBV mouse through the adeno-associated virus. Therefore, the extracellular matrix protein 1 can effectively promote the removal of HBV, and provides higher possibility for functional healing of HBV infection.

The invention discloses an anti-hepatitis B E antigen (HBeAg) antibody or a functional fragment thereof and application thereof. The anti-HBeAg antibody or the functional fragment thereof disclosed by the invention comprises a heavy chain complementarity determining region and a light chain complementarity determining region, and the antibody or the functional fragment thereof has relatively good specificity and sensitivity to HBeAg, and can be used for detecting the HBeAg and diagnosing or assisting in diagnosing related diseases taking the HBeAg as a marker.

The invention provides a hepatitis B treatment time prediction method and device based on a neural network model, and is applied to the technical field of data processing. Data cleaning and missing value supplement processing are performed on clinical parameter information of a target user and different frequency access values of the target user in a preset time period, a target access value of the target user in the preset time period is generated, and the target access value of the target user in the preset time period comprises at least two of HBsAg, HBeAg, HBVDNA, HBsAb, HBeAb and Alt; processing the living habit information of the target user to generate a dynamic risk adjustment factor; processing the target access value and the dynamic risk adjustment factor of the target user in a preset time period based on a target recurrent neural network-long short-term memory network model, and generating an access prediction value of the target user in a target time period; and processing the access prediction value of the target user in the target time period to generate drug healing prediction time information of the target user.

The invention provides application of a BTLA inhibitor in preparation of a medicine for preventing and / or treating chronic hepatitis B, and belongs to the technical field of biological medicine. Research finds that antagonistic B and T lymphocyte attenuation factors (BTLA) can promote removal of hepatitis B surface antigen (HBsAg), reduce the expression level of HBeAg, promote activation and proliferation of T cells and enhance host immune response, so that the purpose of preventing and / or treating chronic hepatitis B is achieved, and functional cure of chronic hepatitis B (CHB) is achieved. The invention provides more choices for medicines for clinically preventing and / or treating chronic hepatitis B.

The present application belongs to the technical field of medicine, and particularly relates to a traditional Chinese medicine composition with the effect of preventing and / or treating hepatitis B. The traditional Chinese medicine composition is mainly prepared from Notopterygium incisum, Angelica pubescens, Poria cocos, Saposhnikovia divaricata, Schizonepeta tenuifolia, Chuanxiong, Platycodon grandiflorum, Bupleurum chinense, Peucedanum praeruptorum, Citrus aurantium, and Glycyrrhiza uralensis. The traditional Chinese medicine composition can not only significantly inhibit the activity of hepatitis B virus, but also significantly inhibit the secretion of HBSAg and HBeAg of hepatitis B virus, inhibit rebound after drug withdrawal, has a significant preventive and / or therapeutic effect on liver damage caused by hepatitis B virus infection, and can promote the production of hepatitis B surface antibody, thus having a broad clinical application prospect.

The invention provides an antibody for resisting an asialoglycoprotein receptor as well as a preparation method and application of the antibody. The antibody for resisting the asialoglycoprotein receptor comprises a heavy chain variable region and a light chain variable region, the heavy chain variable region comprises a heavy chain variable region HCDR1-HCDR3; and the light chain variable region comprises a light chain variable region LCDR1-LCDR3. According to the present invention, the affinity of the anti-asialoglycoprotein receptor antibody to the human asialoglycoprotein receptor is 0.425 nM, and the antigen recognition ability is strong; the compound disclosed by the invention can be used for remarkably inhibiting the DNA expression of HBsAg, HBeAg and HBV of HepG2.2. 15 cells and HepAD38 cells, has a function of inhibiting the replication of the hepatitis B virus, and has a great application prospect in medicines for preventing and / or treating hepatitis B virus infection and / or preventing and / or treating related diseases caused by the hepatitis B virus infection.

The present disclosure provides an antisense oligonucleotide for reducing HBV gene expression and use thereof. The antisense oligonucleotide comprises a 5' wing, a central DNA region and a 3' wing; the antisense oligonucleotide satisfies one or more of the following conditions: (i) the nucleotide sequence of the 5' wing comprises the nucleotide sequence shown in any one of SEQ ID NOs: 181-186 or a modified sequence thereof; (ii) the nucleotide sequence of the central DNA region comprises the nucleotide sequence shown in any one of SEQ ID NOs: 13-18 or a modified sequence thereof; (iii) the nucleotide sequence of the 3' wing comprises the nucleotide sequence shown in any one of SEQ ID NOs: 189-194 or a modified sequence thereof. The antisense oligonucleotide of the present disclosure and / or the modified product thereof can significantly reduce the levels of HBsAg, HBeAg and HBV DNA in serum.

The invention discloses a nano antibody targeting a hepatitis B core antigen as well as a coding gene and application thereof, and relates to the technical field of biological medicines. The nano antibody comprises an amino acid sequence as shown in any one of SEQ ID NO: 1 to SEQ ID NO: 5, and can be specifically combined with HBcAg. The invention also relates to a coding nucleic acid, an expression vector, a host cell and a preparation method of the nano antibody, and application of the nano antibody in preparation of anti-hepatitis B virus drugs and diagnostic reagents. Experiments show that the nano antibody has high affinity of targeting HBcAg, can combine and destroy hepatitis B virus nucleocapsid assembly and inhibit secretion of virus proteins such as HBsAg, HBeAg and the like, and thus has good anti-hepatitis B virus activity.

The invention discloses a dehydrocostunolide derivative as well as a preparation method and medical application thereof, and belongs to the technical field of chemical synthesis, the dehydrocostunolide derivative is shown as a general formula I. The compound has a certain inhibition effect on HBsAg and HBeAg, can be used for preparing anti-HBV drugs, and can be used for preparing medicines for treating HBV. More efficient and safe candidate drug molecules are provided for clinical anti-hepatitis B virus treatment. # imgabs0 #

The invention discloses an application of (R)-HTS-3 in preparation of a medicine for treating hepatitis B. The (R)-HTS-3 can inhibit the levels of HBsAg, HBeAg, HBc, 3.5 kb HBV RNA, HBV core-associated DNA and HBV cccDNA in HBV replication cells, namely can inhibit HBV replication, has low toxicity to hepatocytes, can be used for preparing the medicine for treating hepatitis B, and has a good clinical application prospect.

The present invention relates to the technical field of polysaccharide extraction, and particularly to a preparation method of high-content black garlic polysaccharide and its application in anti-HBV drugs. Through ultrasonic extraction, impurity removal by ceramic membrane, and retention by a suitable organic membrane, the content of black garlic polysaccharide in the obtained black garlic polysaccharide solution is much higher than that of the ordinary water extraction and alcohol precipitation method; after the black garlic polysaccharide solution is dried, the content of black garlic polysaccharide is greater than 85%. In addition, the black garlic polysaccharide prepared by using the preparation method provided by the present invention can reduce the levels of HBsAg and HBeAg and inhibit the replication of HBV-DNA, that is, the black garlic polysaccharide can be used for anti-HBV infection or for the preparation of anti-HBV infection drugs.

The present invention discloses a strain of Bifidobacterium longum GY2 with anti-hepatitis B virus function and its application. The preservation number of the Bifidobacterium longum GY2 is: GDMCC No: 64873. The Bifidobacterium longum GY2 provided by the present invention can inhibit the replication of HBV DNA and the production of HBeAg and HBsAg both in vivo and in vitro, and can delay the occurrence of tumors in nude mice bearing tumors, and has a certain gastrointestinal fluid tolerance ability, can colonize in the intestine, effectively antagonize multiple pathogenic bacteria, is sensitive to multiple antibiotics, has no hemolytic activity, has good probiotic properties and safety, and has significant functions in vivo and in vitro, which has great application potential and utilization value in the development of functional foods or medicines for preventing and treating HBV infection and related diseases.

The application relates to application of extracellular matrix protein 1 in preparation of a medicine for treating HBV infection, and belongs to the technical field of biological medicine. The application provides application of extracellular matrix protein 1 and / or a promoter of extracellular matrix protein 1 in preparation of a medicine for preventing and / or treating HBV infection and diseases caused by the HBV infection. Experiments show that overexpression of the extracellular matrix protein 1 in the liver can significantly reduce the levels of HBsAg and HBeAg in HBV mice, and promote the production of HBsAb in the HBV mice; meanwhile, the expression of the extracellular matrix protein 1 in the liver stellate cells of the HBV mice is supplemented by using an adenovirus, and the extracellular matrix protein 1 is supplemented from outside, which can also significantly reduce the levels of HBsAg and HBeAg in the HBV mice. It can be seen that the extracellular matrix protein 1 can effectively promote the clearance of the HBV, and provide higher possibility for functional cure of the HBV infection.

The invention discloses an anti-hepatitis B E antigen (HBeAg) antibody or a functional fragment thereof and application thereof. The anti-HBeAg antibody or the functional fragment thereof disclosed by the invention comprises a heavy chain complementarity determining region and a light chain complementarity determining region, and the antibody or the functional fragment thereof has relatively good specificity and sensitivity to HBeAg, and can be used for detecting the HBeAg and diagnosing or assisting in diagnosing related diseases taking the HBeAg as a marker.

Provided herein are compositions of CD1280 binding proteins and a Hepatitis B virus core antigen (HBcAg) and / or a Hepatitis B virus E antigen (HBeAg), or antigenic fragments or mutants thereof, attached to the CD180 binding protein, and methods for using the compositions to treat or limit the development of hepatitis-B virus (HBV)-related disorders.

The present disclosure relates to siRNA for interfering with hepatitis B virus and uses thereof. Specifically, the invention relates to an oligonucleotide for inhibiting HBV or a pharmaceutically acceptable salt thereof, the oligonucleotide comprises an antisense strand, and the antisense strand has a sequence as shown in any one of SEQ ID NO: 251-345 or a fragment thereof, or a modification sequence of the sequence or the fragment thereof. The siRNA has a remarkable inhibition effect on HBsAg, HBV DNA and HBeAg generated by HBV DNA integrated by cccDNA and a host genome in vivo and in vitro, and the drug effect is lasting.

The present application relates to the technical field of antibody drugs, and particularly relates to a binding molecule against hepatitis B virus core antigen HBcAg and application thereof. The binding molecule provided by the present application comprises at least one immunoglobulin single variable domain, and the amino acid sequences of CDR1, CDR2 and CDR3 in the immunoglobulin single variable domain are respectively shown as SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3. The binding molecule against hepatitis B virus core antigen provided by the present application can reduce the levels of HBcAg, HBeAg, HBsAg and HBV DNA, and can also reduce the assembly of infectious hepatitis B virus particles, block the secretion of infectious hepatitis B virus complete particles, inhibit the infection and amplification of hepatitis B virus, and has a significant therapeutic effect on hepatitis B.

The invention discloses an infectious disease marker composite quality control product as well as a preparation method and application thereof. The composite quality control product comprises the following components: a matrix liquid, 0.1-1 v / v% of a surfactant, 0.1-1 v / v% of a preservative, 1-5 g / L of a protein amino acid stabilizer, 1-10 g / L of trehalose, 1-10 g / L of (NH4) 2SO4 and five infectious disease markers including a hepatitis B virus surface antigen (HBsAg), a hepatitis B virus e antigen (HBeAg), a hepatitis C virus antibody (Anti-HCV), a human immunodeficiency virus antibody (Anti-HIV) and a treponema pallidum antibody (Anti-TP). The matrix liquid comprises 25-50 v / v% of human serum and a buffer solution. According to the invention, the five infectious disease markers are compounded, and the operation steps of a laboratory are reduced, so that the detection efficiency is improved, and the possibility of human errors is reduced. The composite quality control product can adapt to various mainstream detection instruments, meets the quality control requirements of different laboratories, and has strong market competitiveness.